Our mission is to become a transnational pharmaceutical company through the development and introduction of a wide portfolio of branded and generic products in key markets.
GENERICS
Lupin Pharmaceuticals, Inc. entered the U.S. generic pharmaceutical market in 2003 with the ANDA approval for cefuroxime axetil.
SPECIALTY
We are very pleased to be able to bring Suprax® an important anti-infective product in pediatric practice, back to the US market.
API
We are recognized as a leading manufacturer of cephalosporin API’s, with FDA approval to manufacture complex oral and injectable cephalosporins.
LUPIN
Lupin is amongst the world's largest manufacturers of products in its chosen therapeutic areas.
Lupin receives USFDA approval for Divalproex Sodium Delayed-Release Tablets
Lupin appoints New NCE Research Head.
Lupin Enters Into Marketing Alliance with ASCEND Therapeutics for SUPRAX® 400 mg Tablets in the U.S.
Lupin receives USFDA approval for Escitalopram Oxalate Tablets
Lupin launches Ramipril capsules
Lupin Receives “Best New Manufacturer of the Year” Award from AmerisourceBergen.
Copyright © 2006. All rights reserved.
Created and Designed by
GM